Market Insider
- Stocks Sputter as Investors Seek Catalyst
- Gasoline Price Spike Has Temporary Offset
- Spring Home Buying Season: Good, But Not Good Enough?
- Where’s the French?
- What's Shaking: Wednesday's Early Movers
- Oil Could Turn to Headwind as Dow Flirts With 13,000
- Iran, Economy Threaten Higher Oil Prices
- What's Shaking: Tuesday's Early Movers
- Oil Surges 2% as Iran Halts Some Oil Shipments
- Market Outlook: Everyone Is Waiting for a Stock Pullback
EDITOR
RSS FEED
Major Wave of Biotech Mergers Expected
Text Size 
CNBC Reporter
Amgen [AMGN
Loading...
()
] and Celgene [CELG
Loading...
()
], looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.
 |
Tom Grill | Getty Images |
Amgen is buying Micromet for $1.16 billion at a 33 percent premium to its market price.
Micromet has several cancer drugs in development, including a specific compound for leukemia that the company has in a late-stage trial. Analysts say this is a worthwhile acquisition for Amgen as the biotech firm has been looking for ways to strengthen its position in oncology.
There have been four biotech deals already this year. Analysts expect the merger wave to continue and to specifically target companies with phase II or III drugs in the pipeline. They are of special interest to the bigger pharmaceutical companies, which have strong cash flow but not much in their own research pipelines and older drugs coming off patent.
Some companies that the street has identified as possible acquisition targets include Idenix Pharmaceuticals [IDIX
Loading...
()
], BioMarin Pharmaceuticals [BMRN
Loading...
()
], Pharmacyclics [PCYC
Loading...
()
] and Achillion Pharmaceuticals [ACHN
Loading...
()
]. All of these smaller biotech names have promising drugs in trial that could yield high profitability.
Also Thursday, Celgene announced the acquisition of a privately-held biotech company, Avila Therapeutics for $925 million. This acquisition will give Celgene the ability to expand its role in the hematologic cancer and therapeutics space. Avila Therapeutics specializes in hematology drugs and has a Phase I drug that is designed to treat blood cancers, similar to Celgene’s Revlimid drug.
The acquisition should be closed by March of 2012.
The deals follow Wednesday’s hostile bid by Roche for Illumina [ILMN
Loading...
()
], a leader in DNA mapping. Takeover speculation now surrounds its competitor, Life Technologies [LIFE
Loading...
()
], which is rumored to be the next target in the genomics space.
At J.P. Morgan [JPM
Loading...
()
] Health Care conference, Life Technologies announced that it is launching a new genome mapping device that will offer readings for $1,000, a sharp discount from the current price for sequencing DNA.
Genomics is expected to play a larger role in customized health care, thus the reason we’re seeing large pharmaceutical firms invest in this hot space.
Questions? Comments? Email us at
- The economy is heating up but the Fed isn’t letting up. How do you play the fixed-income market?
- With its rich oil reserves and rampant corruption, Azerbaijan poses a dilemma for U.S. policy makers.
- Business owners should occasionally consider giving their work for free. Here are several reasons why.
- GOP Governor Chris Christie wants Warren Buffett to stop talking about higher taxes on the super-rich.
- There’s a shortage of hotel rooms in London for the Olympics, so many locals are renting out their opulent private homes.
- Boston Beer will be creating a special commemorative brew, the Samuel Adams Boston 26.2, to mark this year's Boston Marathon.
Data is a real-time snapshot *Data is delayed at least 15 minutes
